Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR.
Umberto RestelliManuel García-GoñiMichal Lew-StarowiczPawel MierzejewskiSofia SilvolaJacqueline Mayoral-van SonDavide CrocePaola RoccaBenedicto Crespo-FacorroPublished in: Clinical drug investigation (2020)
The use of lurasidone (74 mg) for the treatment of patients affected with schizophrenia, compared with quetiapine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service point of view.